Earnings Call Insights: Pursuit Attractions and Hospitality (PRSU) Q1 2026 Management view "We delivered record first quarter results. Revenue grew 37%, and we delivered meaningful margin improvement," said President, CEO & Director David Barry, adding that the quarter reflected "healthy demand across our year-round experiences" and "continued discipline on costs." (President, CEO & Director David...
Earnings Call Insights: Pursuit Attractions and Hospitality (PRSU) Q1 2026 Management view "We delivered record first quarter results. Revenue grew 37%, and we delivered meaningful margin improvement," said President, CEO & Director David Barry, adding that the quarter reflected "healthy demand across our year-round experiences" and "continued discipline on costs." (President, CEO & Director David Barry) On Tabacon (Costa Rica), Barry said it "delivered strong performance with $10 million of revenue in the quarter" and that leadership "made smart operational adjustments to drive volume growth through its thermal river attractions." (President, CEO & Director David Barry) On capital allocation, Barry said Pursuit has "repurchased $40.4 million at an average price of $35.40" and that "with the recent approval from our Board to increase our authorization by another $50 million, we have approximately $60 million remaining for future repurchases." (President, CEO & Director David Barry) "Our first quarter revenue grew 37% to reach a record level of $51.6 million," said Chief Financial Officer Michael Heitz, who also reported "our unchanged adjusted EBITDA guidance range of $123 million to $133 million" and that the "pending FlyOver sale remains on track and is expected to close in May." (Chief Financial Officer Michael Heitz) Outlook "We continue to expect 2026 to be a pivotal year for execution of large-scale multiyear, high-return growth projects, combined with continued strong profitable growth," Heitz said, reiterating "our unchanged adjusted EBITDA guidance range of $123 million to $133 million." (Chief Financial Officer Michael Heitz) Heitz said the company now anticipates "investing $70 million to $80 million into growth capital expenditures during 2026" and that this "growth CapEx guidance range has been reduced relative to our prior guidance due to a shift in the expected timing of cash outlays from 2026 to 2027" while "project completion time lines remain on tr...
AlexSecret/E+ via Getty Images Quarterly review The Large Cap Core Fund outperformed the S&P 500 Index benchmark for the quarter. For the three-month period, financials, health care, and energy contributed to relative performance. Industrials, communication services, and consumer staples detracted from relative performance. Market review U.S. equities faced a challenging start to 2026, with the S&...
AlexSecret/E+ via Getty Images Quarterly review The Large Cap Core Fund outperformed the S&P 500 Index benchmark for the quarter. For the three-month period, financials, health care, and energy contributed to relative performance. Industrials, communication services, and consumer staples detracted from relative performance. Market review U.S. equities faced a challenging start to 2026, with the S&P 500 Index declining 4.33% during a volatile first quarter. The pullback snapped a three-quarter streak of positive returns for the S&P 500 Index and represented only the third quarterly decline of the index since 2022. U.S. equities were pressured by persistent inflation concerns, shifting expectations around the pace of Federal Reserve (Fed) rate cuts, and periodic spikes in geopolitical tensions, energy prices, and trade policy uncertainty. Mega-cap technology stocks moderated after strong prior-year gains, with market leadership broadening as investors rotated down the market-cap spectrum and toward more cyclical and rate-sensitive areas. Reflecting this shift, U.S. small- and mid-cap stocks outperformed large caps, with the Russell 2000 Index gaining 0.89% and the Russell 2500 Index gaining 2.04%. International equity markets were modestly negative, with the MSCI World ex USA Index (net) declining 0.81% and the MSCI Emerging Markets Index (net) falling 0.17%. Style leadership also shifted meaningfully, with value stocks significantly outperforming growth. March's outbreak of military conflict between the U.S., Israel, and Iran sparked supply disruptions around the Strait of Hormuz, sending oil prices to their highest levels since mid-2022, with West Texas Intermediate crude oil prices ending the quarter 75% higher. February's Consumer Price Index (CPI) report showed continued disinflation, with headline U.S. inflation easing to +2.4% year over year and core CPI slowing to +2.5%, marking their lowest reading since early 2021. Shelter inflation continued to moderate, go...
Seeking Alpha Seeking Alpha Seeking Alpha Seeking Alpha Seeking Alpha Seeking Alpha Seeking Alpha Seeking Alpha More on Shell Shell Consolidates Its Upstream And LNG Position With ARC Resources Acquisition Shell: Refocusing Will Take Time (Probably A Few Years) Shell: The Company Should Be A Buy, But Near-Term Risks Warrant Patience Shell reports mixed Q1 results; gives Q2 and updates FY26 outlook...
Seeking Alpha Seeking Alpha Seeking Alpha Seeking Alpha Seeking Alpha Seeking Alpha Seeking Alpha Seeking Alpha More on Shell Shell Consolidates Its Upstream And LNG Position With ARC Resources Acquisition Shell: Refocusing Will Take Time (Probably A Few Years) Shell: The Company Should Be A Buy, But Near-Term Risks Warrant Patience Shell reports mixed Q1 results; gives Q2 and updates FY26 outlook Shell earnings preview: Q1 profit seen surging 140%, investors weigh Middle East geopolitical risks
Earnings Call Insights: Biote (BTMD) Q1 2026 Management view CEO Bret Christensen said the quarter was shaped by the company’s operational work on clinic growth and support, but also by a voluntary recall-related disruption: “Over the past 12 months, we have made important progress to advance our strategic priorities. We have strengthened our commercial organization, expanded our sales team and en...
Earnings Call Insights: Biote (BTMD) Q1 2026 Management view CEO Bret Christensen said the quarter was shaped by the company’s operational work on clinic growth and support, but also by a voluntary recall-related disruption: “Over the past 12 months, we have made important progress to advance our strategic priorities. We have strengthened our commercial organization, expanded our sales team and enhanced our capabilities to better support practitioners and their patients.” Christensen tied Q1 performance pressure directly to the January voluntary withdrawal of certain pellet inventory: “This temporary supply disruption created a headwind to our first quarter performance, resulting in an estimated $1.7 million revenue impact and approximately $1.5 million of incremental costs incurred due to the voluntary recall.” He added the salesforce was diverted from growth: “The recall affected our first quarter results and was a significant distraction to our sales force and their growth objectives as they were forced to service accounts versus focusing on growth.” Christensen emphasized commercial capacity expansion despite the disruption: “I'm pleased to report that we are substantially complete with this effort with over 25 new sales personnel hired in the first quarter.” He also pointed to practitioner additions as a leading indicator: “In the first quarter, we trained more than 200 new practitioners, representing a 16.5% increase from the first quarter of 2025.” CFO Robert Peterson summarized the quarter’s financial pressure and mix shift: “Revenue decreased 8.3% to $44.9 million, with procedure revenue declining 13.2% to $31.3 million, which included a $1.7 million impact related to the voluntary recall of certain hormone pellets shipped by Asteria Health.” Outlook Peterson reiterated full-year targets while acknowledging a weaker first-half procedure cadence tied to the recall: “We maintain our guidance, forecasting 2026 revenue above $190 million and 2026 adjusted EBITD...
(RTTNews) - InterContinental Hotels Group PLC (IHG, IHG.L) reported Thursday very strong first-quarter trading performance, with growth of 4.4 percent in Global RevPAR.
(RTTNews) - InterContinental Hotels Group PLC (IHG, IHG.L) reported Thursday very strong first-quarter trading performance, with growth of 4.4 percent in Global RevPAR.
Angelini Pharma has agreed to acquire all outstanding shares of Catalyst Pharmaceuticals ( CPRX ) for $31.50 per share in cash, for a total equity value of approximately $4.1B. The deal has been unanimously approved by the boards of directors of both companies and is expected to close in the third quarter of 2026. The consideration represents a premium of 28% to Catalyst’s 30-day volume-weighted a...
Angelini Pharma has agreed to acquire all outstanding shares of Catalyst Pharmaceuticals ( CPRX ) for $31.50 per share in cash, for a total equity value of approximately $4.1B. The deal has been unanimously approved by the boards of directors of both companies and is expected to close in the third quarter of 2026. The consideration represents a premium of 28% to Catalyst’s 30-day volume-weighted average trading price as of April 22, 2026. Founded in 2002 and listed on Nasdaq since 2006, Catalyst has built a portfolio of products focused on the treatment of rare neuromuscular and neurological diseases. Following completion of the acquisition, Angelini Pharma plans to integrate Catalyst’s portfolio and commercial infrastructure with its own expertise and products in Brain Health to develop a next-generation therapeutic platform in Rare Diseases. The transaction will be carried out with the participation of Blackstone ( BX ) funds and select international partners, and will be financed with the support of BNP Paribas. CPRX shares fell 1.9% premarket on Thursday. More on Catalyst Pharmaceuticals, Inc. Catalyst Pharmaceuticals: Favorable Trial Outcome Could Be A Meaningful Overhang Catalyst Pharmaceuticals, Inc. (CPRX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript Catalyst Pharmaceuticals, Inc. (CPRX) Q4 2025 Earnings Call Transcript Catalyst Pharmaceuticals jumps on report of interest from Angelini Pharma Catalyst forecasts 21–26% FIRDAPSE revenue growth in 2026 while expanding AGAMREE market penetration
(RTTNews) - ENGIE (ENGI.PA) reported first quarter EBITDA of 4.7 billion euros, down 13.6% on a gross basis and down 12.3% on an organic basis. EBITDA ex. Nuclear was 4.6 billion euros, was down 6.0% on a gross basis and down 4.4% on an organic basis. EBIT ex. Nuclear was at 3.4
(RTTNews) - ENGIE (ENGI.PA) reported first quarter EBITDA of 4.7 billion euros, down 13.6% on a gross basis and down 12.3% on an organic basis. EBITDA ex. Nuclear was 4.6 billion euros, was down 6.0% on a gross basis and down 4.4% on an organic basis. EBIT ex. Nuclear was at 3.4
Vonovia SE press release ( VONOY ): Q1 Non-GAAP EPS of €0.43. Revenue of €1.26B (+0.8% Y/Y). More on Vonovia SE Vonovia: Long Idea With Attractive Dividend Yield And Solid Future Returns Vonovia: Recent Pullback Provides A Buying Opportunity Vonovia SE 2025 Q4 - Results - Earnings Call Presentation Seeking Alpha’s Quant Rating on Vonovia SE Historical earnings data for Vonovia SE
Vonovia SE press release ( VONOY ): Q1 Non-GAAP EPS of €0.43. Revenue of €1.26B (+0.8% Y/Y). More on Vonovia SE Vonovia: Long Idea With Attractive Dividend Yield And Solid Future Returns Vonovia: Recent Pullback Provides A Buying Opportunity Vonovia SE 2025 Q4 - Results - Earnings Call Presentation Seeking Alpha’s Quant Rating on Vonovia SE Historical earnings data for Vonovia SE